Emer­gent snags opi­oid drug in $735M buy­out deal; Ger­many frets about post-Brex­it dis­rup­tion in drug mar­ket

→ Emer­gent BioSo­lu­tions has struck a $735 mil­lion deal to ac­quire Adapt, which mar­kets an opi­oid over­dose drug called Nar­can. Emer­gent is pay­ing $635 mil­lion of that up­front. The buy­out comes as the US grap­ples with an opi­oid cri­sis that has been dri­ving a con­sid­er­able amount of gov­ern­ment con­tract­ing.

→ Reuters re­ports that Ger­many wants its drug­mak­ers to ex­am­ine the pos­si­bil­i­ty of any new drug short­ages that may be cre­at­ed by Brex­it. The UK’s de­par­ture from the EU has raised re­peat­ed alarms about changes that could roil the in­dus­try — par­tic­u­lar­ly if the with­draw­al comes with­out a deal in place to gov­ern the move.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER